HeartFlow, Inc. (HTFL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

HeartFlow, Inc. (HTFL) Healthcare & Pipeline Overview

HeartFlow, Inc. specializes in non-invasive diagnostic solutions for coronary artery disease, utilizing its AI-powered HeartFlow Platform to create personalized 3D heart models. This technology enhances diagnostic accuracy and treatment planning, positioning HeartFlow as a key innovator in the healthcare information services sector.

What Is the Investment Thesis for HTFL?

HeartFlow, Inc. presents a notable research candidate within the healthcare technology sector, driven by its innovative HeartFlow Platform. The platform's ability to provide detailed, non-invasive assessments of coronary artery disease offers significant value to healthcare providers and patients. Key value drivers include the increasing adoption of the HeartFlow Platform by hospitals and cardiology practices, expansion into new geographic markets, and ongoing advancements in AI and computational fluid dynamics. The company's gross margin of 76.8% indicates strong profitability potential as adoption scales. Potential catalysts include positive clinical trial results and favorable regulatory decisions. However, investors should be aware of risks such as competition from established medical device companies and the need for continuous innovation to maintain a competitive edge.

Based on FMP financials and quantitative analysis

HTFL Key Highlights

Market capitalization of $4.16B reflects investor confidence in HeartFlow's growth potential.

• Gross margin of 76.8% demonstrates strong profitability and efficient cost management.
• The HeartFlow Platform utilizes AI and computational fluid dynamics to create personalized 3D models of the heart, offering a unique and advanced diagnostic tool.
• The company's non-invasive approach reduces the need for more invasive procedures, potentially lowering healthcare costs and improving patient outcomes.
• Operating in the Healthcare Information Services industry, HeartFlow is positioned to benefit from the increasing demand for advanced diagnostic technologies.

Who Are HTFL's Competitors?

HTFL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are HTFL's Key Strengths?

Innovative HeartFlow Platform with AI and computational fluid dynamics.

• Non-invasive diagnostic solution reduces the need for invasive procedures.
• Strong gross margin of 76.8%.
• Established market presence in the non-invasive cardiac imaging space.

What Are HTFL's Weaknesses?

Negative profit margin of -66.3%.

• Reliance on a single product platform.
• Requires continuous innovation to maintain a competitive edge.
• Potential for reimbursement challenges from healthcare payers.

What Could Drive HTFL Stock Higher?

HTFL catalyst: Publication of new clinical trial results demonstrating the clinical and economic benefits of the HeartFlow Platform.

• Increasing adoption of the HeartFlow Platform by hospitals and cardiology practices.
• Expansion into new geographic markets, particularly in Europe and Asia.
• Development of new applications for the HeartFlow Platform beyond coronary artery disease.

What Are the Key Risks for HTFL?

Insider selling — insiders were net sellers of roughly $6.4M recently.

• Competition from established medical device companies with greater resources and market share.
• Technological obsolescence as new diagnostic technologies emerge.
• Regulatory changes and compliance requirements that could increase operating costs.
• Economic downturns and healthcare budget constraints that could reduce demand for the HeartFlow Platform.

What Are the Growth Opportunities for HTFL?

• Expansion into New Geographic Markets: HeartFlow has the opportunity to expand its market presence globally, particularly in regions with high prevalence of coronary artery disease and increasing healthcare expenditure. Entering new markets requires strategic partnerships with local healthcare providers and regulatory approvals. The global market for cardiovascular diagnostic devices is projected to reach $25 billion by 2028, offering substantial growth potential for HeartFlow.
• Development of New Applications for the HeartFlow Platform: HeartFlow can leverage its AI and computational fluid dynamics expertise to develop new applications for its platform beyond coronary artery disease. This includes exploring diagnostic solutions for other cardiovascular conditions, such as heart failure and valvular heart disease. Expanding the platform's capabilities will broaden its market reach and increase its value proposition to healthcare providers.
• Strategic Partnerships with Healthcare Providers: Forming strategic partnerships with leading hospitals and cardiology practices can accelerate the adoption of the HeartFlow Platform. These partnerships can involve integrating the platform into existing clinical workflows, conducting joint research studies, and co-marketing the technology to referring physicians. Collaborations with key opinion leaders in cardiology can also enhance HeartFlow's credibility and market visibility.
• Advancements in AI and Computational Fluid Dynamics: Continued investment in AI and computational fluid dynamics can further enhance the accuracy and efficiency of the HeartFlow Platform. This includes developing more sophisticated algorithms for analyzing blood flow dynamics and improving the visualization of 3D heart models. These advancements will strengthen HeartFlow's competitive advantage and attract new customers.
• Focus on Value-Based Healthcare: As healthcare systems increasingly shift towards value-based care models, HeartFlow is well-positioned to demonstrate the economic benefits of its technology. By reducing the need for invasive procedures and improving patient outcomes, the HeartFlow Platform can help healthcare providers lower costs and improve the quality of care. Emphasizing the value proposition of the platform can drive adoption and market share growth.

What Are HTFL's Competitive Advantages?

• Proprietary AI and computational fluid dynamics technology that is difficult to replicate.
• Extensive clinical validation of the HeartFlow Platform, demonstrating its accuracy and effectiveness.
• Strong relationships with key opinion leaders in cardiology.
• Established market presence and brand recognition in the non-invasive cardiac imaging space.

What Does HTFL Do?

Founded in 2007 and headquartered in Mountain View, California, HeartFlow, Inc. is a medical technology company focused on revolutionizing the diagnosis and management of coronary artery disease. The company's core innovation is the HeartFlow Platform, which employs artificial intelligence and computational fluid dynamics to generate a personalized, three-dimensional model of a patient's heart. This model is derived from standard coronary computed tomography angiography (CTA) scans, providing clinicians with detailed insights into blood flow, stenosis (narrowing of arteries), and the composition of plaque. HeartFlow's technology overcomes the limitations of traditional non-invasive imaging tests, offering a more precise and comprehensive assessment of coronary artery health. By providing detailed information about blood flow dynamics, HeartFlow enables physicians to make more informed decisions regarding patient treatment, potentially reducing the need for invasive procedures. HeartFlow's solutions are used by healthcare providers worldwide, marking its significant global presence. The company continues to innovate in the field of cardiovascular diagnostics, aiming to improve patient outcomes and reduce healthcare costs associated with coronary artery disease.

What Products and Services Does HTFL Offer?

• Develops and markets the HeartFlow Platform, a non-invasive diagnostic tool for coronary artery disease.
• Utilizes AI and computational fluid dynamics to create personalized 3D models of a patient's heart.
• Provides detailed insights into blood flow, stenosis, and plaque composition.
• Offers a more precise and comprehensive assessment of coronary artery health compared to traditional non-invasive imaging tests.
• Helps physicians make more informed decisions regarding patient treatment.
• Reduces the need for invasive procedures, potentially lowering healthcare costs and improving patient outcomes.

How Does HTFL Make Money?

• Generates revenue through the sale of the HeartFlow Platform to hospitals and cardiology practices.
• Offers subscription-based access to the platform, providing ongoing software updates and support.
• Charges fees per patient scan analyzed using the HeartFlow Platform.
• May generate revenue through strategic partnerships with healthcare providers and research institutions.

What Industry Does HTFL Operate In?

HeartFlow operates within the rapidly evolving healthcare information services industry, which is experiencing significant growth due to increasing demand for advanced diagnostic technologies and personalized medicine. The market for non-invasive cardiac imaging is expanding, driven by the need for more accurate and cost-effective diagnostic solutions. HeartFlow's competitive landscape includes established medical device companies and emerging technology firms. The company's AI-powered HeartFlow Platform differentiates it from competitors by providing detailed insights into blood flow dynamics and plaque composition, enhancing diagnostic accuracy and treatment planning.

Who Are HTFL's Key Customers?

• Hospitals and cardiology practices seeking to improve the accuracy and efficiency of coronary artery disease diagnosis.
• Cardiologists and other healthcare professionals who use the HeartFlow Platform to guide treatment decisions.
• Patients with suspected or known coronary artery disease who undergo HeartFlow analysis as part of their diagnostic workup.
• Research institutions and pharmaceutical companies conducting clinical trials related to cardiovascular disease.

Company Profile

HeartFlow, Inc. operates in the Medical - Healthcare Information Services industry within the Healthcare sector. It is headquartered in San Francisco, US. The company is led by CEO John Farquhar. HTFL has traded publicly since 2025.

Key Financial Metrics

Return on assets is -32.5%, showing how much profit it generates from its asset base. Its free cash flow yield is -3.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.2%, the inverse of the P/E and a quick read on earnings relative to price.

HTFL Valuation & Market Position

With a $4.16B market cap, HeartFlow, Inc. sits in the mid-cap segment of the market. Analyst price targets span from $37.00 to $55.00, with a consensus of $44.57. At the current price of $48.23, that implies roughly 8% downside from the consensus target. Relative to its peer group, HTFL's quantitative score of 32/100 is below the peer average of 64/100.

Quarterly Financial Performance: HeartFlow, Inc.

Revenue for HeartFlow, Inc. came in at $64.1M during Q2 FY2026, a 21.9% improvement versus the preceding quarter. The company recorded a net loss of $15.7M, with diluted EPS of $-0.18. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this mid-cap Healthcare company. Across the four most recent quarters, HTFL averaged $-0.35 in diluted EPS.

HeartFlow, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 32.85 places it in the safe zone, indicating low near-term bankruptcy risk.

HeartFlow, Inc. has beaten Wall Street's EPS estimate in 4 of its last 6 reported quarters — more hits than misses. Reported results have landed about 3.2% above estimates on average.

Over the past six months, HeartFlow, Inc. insiders filed 28 SEC Form 4 transactions — 21 sales and 7 purchases. On net that is roughly 150K shares disposed (about $6.4M), a signal worth weighing alongside the fundamentals.

HTFL Financials

HTFL Latest News

HTFL Analyst Consensus

HTFL MoonshotScore

HTFL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources